These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27473079)

  • 1. The relationship between the expression of FOXA1 and GATA3 and the efficacy of neoadjuvant endocrine therapy.
    Tanaka K; Tokunaga E; Yamashita N; Sagara Y; Ohi Y; Taguchi K; Ohno S; Okano S; Oda Y; Maehara Y
    Breast Cancer; 2017 May; 24(3):384-392. PubMed ID: 27473079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
    Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
    Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression analysis of invasive breast carcinoma yields differential patterns in luminal subtypes of breast cancer.
    Abdelhafiz AS; Fouda MA; Elzefzafy NA; Taha II; Mohemmed OM; Alieldin NH; Toony I; Abdel Wahab AA; Farahat IG
    Ann Diagn Pathol; 2021 Dec; 55():151814. PubMed ID: 34517157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
    Kurozumi S; Matsumoto H; Inoue K; Tozuka K; Hayashi Y; Kurosumi M; Oyama T; Fujii T; Horiguchi J; Kuwano H
    PLoS One; 2018; 13(8):e0201846. PubMed ID: 30080878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients.
    Xu C; Wei Q; Guo J; Zhou JC; Mei J; Jiang ZN; Shen JG; Wang LB
    Ann Surg Oncol; 2015; 22(6):2034-9. PubMed ID: 25707489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological analysis of GATA3-positive breast cancers with special reference to response to neoadjuvant chemotherapy.
    Tominaga N; Naoi Y; Shimazu K; Nakayama T; Maruyama N; Shimomura A; Kim SJ; Tamaki Y; Noguchi S
    Ann Oncol; 2012 Dec; 23(12):3051-3057. PubMed ID: 22767585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
    Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
    Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases.
    Horimoto Y; Arakawa A; Harada-Shoji N; Sonoue H; Yoshida Y; Himuro T; Igari F; Tokuda E; Mamat O; Tanabe M; Hino O; Saito M
    Br J Cancer; 2015 Jan; 112(2):345-51. PubMed ID: 25422910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores.
    Ademuyiwa FO; Thorat MA; Jain RK; Nakshatri H; Badve S
    Mod Pathol; 2010 Feb; 23(2):270-5. PubMed ID: 19946260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome.
    Schrijver W; Schuurman K; van Rossum A; Droog M; Jeronimo C; Salta S; Henrique R; Wesseling J; Moelans C; Linn SC; van den Heuvel M; van Diest P; Zwart W
    Mol Oncol; 2018 Nov; 12(11):1884-1894. PubMed ID: 29972720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3.
    Takaku M; Grimm SA; De Kumar B; Bennett BD; Wade PA
    Nucleic Acids Res; 2020 May; 48(9):4756-4768. PubMed ID: 32232341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).
    De Lara S; Nyqvist J; Werner Rönnerman E; Helou K; Kenne Sarenmalm E; Einbeigi Z; Karlsson P; Parris TZ; Kovács A
    BMC Cancer; 2019 Feb; 19(1):187. PubMed ID: 30819139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function.
    Jiang G; Wang X; Sheng D; Zhou L; Liu Y; Xu C; Liu S; Zhang J
    Theranostics; 2019; 9(22):6501-6516. PubMed ID: 31588232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A transcriptional complex composed of ER(α), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast cancer cells.
    Lee JY; Park YJ; Oh N; Kwack KB; Park KS
    Oncotarget; 2017 Jun; 8(26):42752-42760. PubMed ID: 28514748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours.
    Albergaria A; Paredes J; Sousa B; Milanezi F; Carneiro V; Bastos J; Costa S; Vieira D; Lopes N; Lam EW; Lunet N; Schmitt F
    Breast Cancer Res; 2009; 11(3):R40. PubMed ID: 19549328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.